4.7 Review

Copper and Zinc Dysregulation in Alzheimer's Disease

Journal

TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 39, Issue 12, Pages 1049-1063

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2018.10.001

Keywords

-

Funding

  1. Italian Department of Health [RF-2013-02358785, NET-2011-02346784-1]
  2. AIRAlzh Onlus (ANCC-COOP)
  3. Italian Ministry of Health [CO-2016 2361018]
  4. Ricerca Corrente

Ask authors/readers for more resources

Alzheimer's disease (AD) is one of the most common forms of dementia. Despite a wealth of knowledge on the molecular mechanisms involved in AD, current treatments have mainly focused on targeting amyloid beta (A beta) production, but have failed to show significant effects and efficacy. Therefore, a critical reconsideration of the multifactorial nature of the disease is needed. AD is a complex multifactorial disorder in which, along with A beta and tau, the convergence of polygenic, epigenetic, environmental, vascular, and metabolic factors increases the global susceptibility to the disease and shapes its course. One of the cofactors converging on AD is the dysregulation of brain metals. In this review, we focus on the role of AD-related neurodegeneration and cognitive decline triggered by the imbalance of two endogenous metals: copper and zinc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available